| pubmed-article:7967363 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7967363 | lifeskim:mentions | umls-concept:C1257890 | lld:lifeskim |
| pubmed-article:7967363 | lifeskim:mentions | umls-concept:C2290901 | lld:lifeskim |
| pubmed-article:7967363 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:7967363 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:7967363 | lifeskim:mentions | umls-concept:C0538727 | lld:lifeskim |
| pubmed-article:7967363 | lifeskim:mentions | umls-concept:C0017725 | lld:lifeskim |
| pubmed-article:7967363 | lifeskim:mentions | umls-concept:C0031139 | lld:lifeskim |
| pubmed-article:7967363 | lifeskim:mentions | umls-concept:C1261322 | lld:lifeskim |
| pubmed-article:7967363 | lifeskim:mentions | umls-concept:C1423498 | lld:lifeskim |
| pubmed-article:7967363 | lifeskim:mentions | umls-concept:C0037633 | lld:lifeskim |
| pubmed-article:7967363 | lifeskim:mentions | umls-concept:C0031140 | lld:lifeskim |
| pubmed-article:7967363 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:7967363 | lifeskim:mentions | umls-concept:C1561560 | lld:lifeskim |
| pubmed-article:7967363 | lifeskim:mentions | umls-concept:C1561561 | lld:lifeskim |
| pubmed-article:7967363 | lifeskim:mentions | umls-concept:C1547135 | lld:lifeskim |
| pubmed-article:7967363 | lifeskim:mentions | umls-concept:C1547139 | lld:lifeskim |
| pubmed-article:7967363 | lifeskim:mentions | umls-concept:C0439841 | lld:lifeskim |
| pubmed-article:7967363 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:7967363 | pubmed:dateCreated | 1994-12-12 | lld:pubmed |
| pubmed-article:7967363 | pubmed:abstractText | The osmotic effectiveness of a large molecular weight glucose polymer fraction (Icodextrin) as a novel "colloid" osmotic agent in peritoneal dialysis was established, but the long-term safety remained undetermined. A randomized, controlled multicenter investigation of Icodextrin in ambulatory peritoneal dialysis (MIDAS) was undertaken to evaluate the long-term safety and efficacy by comparing daily overnight (8 to 12 hr dwell) use of isosmolar Icodextrin (282 mOsm/kg) with conventional 1.36% (346 mOsm/kg) and 3.86% (484 mOsm/kg) glucose exchanges over six months. Two hundred and nine patients were randomized from 11 centers, with 106 allocated to receive Icodextrin (D) and 103 to remain on glucose (control group; C); 138 patients completed the six month study (71 C, 67 D). All patients were divided into weak (1.36%) or strong (3.86%) subgroups based on their use of glucose solutions overnight during the pretreatment baseline period. The mean (+/- SEM) overnight ultrafiltration (UF) with D was 3.5 times greater than 1.36% glucose at eight hours [527 +/- 36 vs. 150 +/- 47 ml; 95% confidence interval (CI) for the difference +257 to +497 ml; P < 0.0001] and 5.5 times greater at 12 hours (561 +/- 44 vs. 101 +/- 48 ml, 95% CI for the difference +329 to +590; P < 0.0001) and no different from that of 3.86% glucose at eight hours (510 +/- 48 vs. 448 +/- 60 ml, 95% CI for the difference -102 to +226 ml; P = 0.44) and at 12 hours (552 +/- 44 vs. 414 +/- 78 ml, 95% CI for the difference -47 to +325 ml; P = 0.06).(ABSTRACT TRUNCATED AT 250 WORDS) | lld:pubmed |
| pubmed-article:7967363 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7967363 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7967363 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7967363 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7967363 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7967363 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7967363 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7967363 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7967363 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7967363 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:7967363 | pubmed:issn | 0085-2538 | lld:pubmed |
| pubmed-article:7967363 | pubmed:author | pubmed-author:GokalRR | lld:pubmed |
| pubmed-article:7967363 | pubmed:author | pubmed-author:MistryC DCD | lld:pubmed |
| pubmed-article:7967363 | pubmed:author | pubmed-author:PeersEE | lld:pubmed |
| pubmed-article:7967363 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7967363 | pubmed:volume | 46 | lld:pubmed |
| pubmed-article:7967363 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7967363 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7967363 | pubmed:pagination | 496-503 | lld:pubmed |
| pubmed-article:7967363 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:7967363 | pubmed:meshHeading | pubmed-meshheading:7967363-... | lld:pubmed |
| pubmed-article:7967363 | pubmed:meshHeading | pubmed-meshheading:7967363-... | lld:pubmed |
| pubmed-article:7967363 | pubmed:meshHeading | pubmed-meshheading:7967363-... | lld:pubmed |
| pubmed-article:7967363 | pubmed:meshHeading | pubmed-meshheading:7967363-... | lld:pubmed |
| pubmed-article:7967363 | pubmed:meshHeading | pubmed-meshheading:7967363-... | lld:pubmed |
| pubmed-article:7967363 | pubmed:meshHeading | pubmed-meshheading:7967363-... | lld:pubmed |
| pubmed-article:7967363 | pubmed:meshHeading | pubmed-meshheading:7967363-... | lld:pubmed |
| pubmed-article:7967363 | pubmed:meshHeading | pubmed-meshheading:7967363-... | lld:pubmed |
| pubmed-article:7967363 | pubmed:meshHeading | pubmed-meshheading:7967363-... | lld:pubmed |
| pubmed-article:7967363 | pubmed:meshHeading | pubmed-meshheading:7967363-... | lld:pubmed |
| pubmed-article:7967363 | pubmed:meshHeading | pubmed-meshheading:7967363-... | lld:pubmed |
| pubmed-article:7967363 | pubmed:meshHeading | pubmed-meshheading:7967363-... | lld:pubmed |
| pubmed-article:7967363 | pubmed:meshHeading | pubmed-meshheading:7967363-... | lld:pubmed |
| pubmed-article:7967363 | pubmed:meshHeading | pubmed-meshheading:7967363-... | lld:pubmed |
| pubmed-article:7967363 | pubmed:meshHeading | pubmed-meshheading:7967363-... | lld:pubmed |
| pubmed-article:7967363 | pubmed:meshHeading | pubmed-meshheading:7967363-... | lld:pubmed |
| pubmed-article:7967363 | pubmed:meshHeading | pubmed-meshheading:7967363-... | lld:pubmed |
| pubmed-article:7967363 | pubmed:year | 1994 | lld:pubmed |
| pubmed-article:7967363 | pubmed:articleTitle | A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Peritoneal Dialysis. | lld:pubmed |
| pubmed-article:7967363 | pubmed:affiliation | Institute of Nephrology, Cardiff Royal Infirmary, Wales, United Kingdom. | lld:pubmed |
| pubmed-article:7967363 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7967363 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:7967363 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:7967363 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:7967363 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:7967363 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7967363 | lld:pubmed |
